See more : I Synergy Group Limited (IS3.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Atossa Therapeutics, Inc. (ATOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Atossa Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Huali Industrial Group Company Limited (300979.SZ) Income Statement Analysis – Financial Results
- Yowie Group Limited (YWGRF) Income Statement Analysis – Financial Results
- Remark Holdings, Inc. (MARK) Income Statement Analysis – Financial Results
- Recruit Holdings Co., Ltd. (6098.T) Income Statement Analysis – Financial Results
- Gaensel Energy Group, Inc. (GEGR) Income Statement Analysis – Financial Results
Atossa Therapeutics, Inc. (ATOS)
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.76K | 525.95K | 632.56K | 481.84K | 1.50K | 0.00 | 0.00 |
| Cost of Revenue | 23.00K | 8.00K | 23.00K | 46.60K | 52.79K | 44.20K | 128.99K | 303.48K | 132.41K | 340.66K | 495.47K | 65.63K | 97.19K | 0.00 | 0.00 |
| Gross Profit | -23.00K | -8.00K | -23.00K | -46.60K | -52.79K | -44.20K | -128.99K | -303.48K | -130.65K | 185.30K | 137.09K | 416.21K | -95.69K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7,431.91% | 35.23% | 21.67% | 86.38% | -6,379.33% | 0.00% | 0.00% |
| Research & Development | 17.33M | 15.08M | 9.21M | 6.61M | 6.65M | 4.21M | 2.33M | 770.43K | 2.36M | 2.58M | 1.11M | 1.97K | 0.00 | 120.00K | 21.25K |
| General & Administrative | 14.04M | 12.61M | 11.31M | 8.00M | 10.62M | 7.22M | 4.86M | 6.48M | 8.85M | 8.63M | 8.56M | 5.02M | 3.17M | 882.16K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42M | 1.27M | 1.26M | 466.82K | 160.85K | 12.20K | 0.00 |
| SG&A | 14.04M | 12.61M | 11.31M | 8.00M | 10.62M | 7.22M | 4.86M | 6.48M | 10.27M | 9.90M | 9.82M | 5.49M | 3.33M | 894.36K | 101.61K |
| Other Expenses | 0.00 | -146.00K | -85.00K | 50.80K | 25.65K | 29.30K | 154.00 | 718.97K | 0.00 | 2.01M | 0.00 | 0.00 | 0.00 | 63.64K | 0.00 |
| Operating Expenses | 31.38M | 27.69M | 20.52M | 14.61M | 17.27M | 11.43M | 7.19M | 7.25M | 12.63M | 12.48M | 10.92M | 5.49M | 3.33M | 1.08M | 122.86K |
| Cost & Expenses | 31.38M | 27.69M | 20.52M | 14.61M | 17.27M | 11.43M | 7.19M | 7.25M | 12.76M | 12.82M | 11.42M | 5.55M | 3.43M | 1.08M | 122.86K |
| Interest Income | 4.34M | 877.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 260.00 | 295.00 | 1.22K | 4.91K | 455.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 192.82K | 0.00 | 0.00 | 15.77K | 360.00 | 12.04K | 17.99K | 9.14K | 0.00 |
| Depreciation & Amortization | 23.00K | 8.00K | 23.00K | 46.60K | 52.79K | 44.20K | 128.99K | 303.48K | 272.63K | 564.46K | 472.93K | 130.55K | 15.62K | 455.00 | 0.00 |
| EBITDA | -31.35M | -27.68M | -20.50M | -14.56M | -17.21M | -11.39M | -7.80M | -6.37M | -12.49M | -9.35M | -10.31M | -4.94M | -3.41M | -1.09M | -122.86K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -710,262.91% | -2,336.62% | -1,630.11% | -1,024.66% | -227,243.60% | 0.00% | 0.00% |
| Operating Income | -31.38M | -27.69M | -20.52M | -14.61M | -17.27M | -11.43M | -7.65M | -7.97M | -12.76M | -14.64M | -10.78M | -5.07M | -3.43M | -1.08M | -122.86K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -725,746.19% | -2,783.97% | -1,704.93% | -1,052.01% | -228,612.67% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.28M | 731.00K | -85.00K | -3.22M | 25.65K | 29.30K | -473.41K | 0.00 | 431.00 | -2.49M | -65.00 | -10.82K | -13.08K | -8.68K | 0.00 |
| Income Before Tax | -30.09M | -26.96M | -20.61M | -17.83M | -17.24M | -11.40M | -8.12M | -6.37M | -12.76M | -14.66M | -10.78M | -5.08M | -3.44M | -1.09M | -122.86K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -725,721.67% | -2,786.92% | -1,704.94% | -1,054.26% | -229,484.60% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -731.00K | -213.56K | 3.27M | -119.07K | -29.30K | 742.46K | -1.76M | 3.00M | 2.35M | 65.00 | 10.82K | 13.08K | 250.00 | 0.00 |
| Net Income | -30.09M | -26.23M | -20.61M | -21.10M | -17.24M | -11.40M | -8.12M | -6.37M | -15.76M | -14.66M | -10.78M | -5.08M | -3.44M | -1.09M | -122.86K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -896,491.64% | -2,786.92% | -1,704.94% | -1,054.26% | -229,484.60% | 0.00% | 0.00% |
| EPS | -0.24 | -0.21 | -0.18 | -1.87 | -2.03 | -2.74 | -8.33 | -25.93 | -99.79 | -109.76 | -125.37 | -73.43 | -67.96 | -32.96 | -2.42 |
| EPS Diluted | -0.24 | -0.21 | -0.18 | -1.87 | -2.03 | -2.74 | -8.33 | -25.93 | -99.79 | -109.76 | -125.37 | -73.43 | -67.96 | -32.58 | -2.42 |
| Weighted Avg Shares Out | 126.08M | 126.62M | 116.95M | 11.31M | 8.50M | 4.16M | 974.77K | 245.61K | 157.93K | 133.55K | 86.02K | 69.18K | 50.65K | 32.98K | 50.77K |
| Weighted Avg Shares Out (Dil) | 126.08M | 126.62M | 116.95M | 11.31M | 8.50M | 4.16M | 974.77K | 245.61K | 157.93K | 133.55K | 86.02K | 69.18K | 50.65K | 33.36K | 50.77K |
Atossa Therapeutics welcomes updated breast cancer screening guidelines
Atossa Therapeutics Inc (NASDAQ:ATOS) has welcomed new guidelines released by the US Preventative Services Task Force that recommend women begin breast cancer screening starting at age 40. The biopharmaceutical company targeting breast cancer with its lead asset (Z)-endoxifen highlighted that...
Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced its support of new guidelines released by the U.S. Preventive Services Task Force (USPSTF) recommending that women begin breast cancer screening starting...
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced an expanded research agreement with Weill Cornell Medicine to explore the potential synergy between antibody drug conjugates (ADCs) and (Z)-endoxifen. Atossa is...
Atossa Therapeutics announces breast cancer trial evaluating lead asset in combination with Eli Lilly drug
Atossa Therapeutics Inc (NASDAQ:ATOS) and its research partner Quantum Leap Healthcare Collaborative announced the initiation of a new study evaluating Atossa's lead drug candidate (Z)-endoxifen in combination with Eli Lilly and Co (NYSE:LLY)'s abemaciclib (VERZENIO) in women with Estrogen Receptor...
Atossa Therapeutics announces breast cancer trial evaluating lead asset in combination with Eli Lilly drug
Atossa Therapeutics Inc (NASDAQ:ATOS) and its research partner Quantum Leap Healthcare Collaborative announced the initiation of a new study evaluating Atossa's lead drug candidate (Z)-endoxifen in combination with Eli Lilly and Co (NYSE:LLY)'s abemaciclib (VERZENIO) in women with Estrogen Receptor...
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new study to evaluate Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a...
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April...
Atossa Therapeutics reports positive data from breast cancer treatment trial
Atossa Therapeutics Inc (NASDAQ:ATOS) unveiled encouraging safety and efficacy findings from its Phase 2 EVANGELINE clinical trial evaluating (Z)-endoxifen as a neoadjuvant therapy for breast cancer. Data presented at the American Association for Cancer Research (AACR) Annual Meeting showed that...
Atossa Therapeutics reports positive data from breast cancer treatment trial
Atossa Therapeutics Inc (NASDAQ:ATOS) unveiled encouraging safety and efficacy findings from its Phase 2 EVANGELINE clinical trial evaluating (Z)-endoxifen as a neoadjuvant therapy for breast cancer. Data presented at the American Association for Cancer Research (AACR) Annual Meeting showed that...
Source: https://incomestatements.info
Category: Stock Reports